Trovagene (TROV) announced preclinical data that evaluated the effect of combining onvansertib with venetoclax in an AML cell model known to be resistant to venetoclax, or Venclexta of AbbVie (ABBV). This combination demonstrated synergy with a significant decrease in tumor cell viability. This data further supports Trovagene’s ongoing onvansertib clinical development program in patients with relapsed/refractory AML, for which there are limited treatment options and the prognosis is poor. The Company is currently conducting a Phase 1b/2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy in patients with relapsed or refractory AML at nine sites across the U.S. and recently presented encouraging safety and preliminary efficacy data at the American Association for Clinical Research conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.